60.2 Parkinson's Disease & Essential Tremor

Neurobiology & Cardinal Motor Manifestations of Parkinson's Disease

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. The fundamental neuropathological hallmark is the progressive degeneration and loss of neuromelanin-containing dopaminergic projection neurons in the substantia nigra pars compacta (SNpc) that project to the dorsal striatum (caudate nucleus and putamen). By the time classical motor symptoms manifest, approximately 50% to 70% of nigrostriatal dopaminergic neurons have already undergone apoptotic degeneration, with an 80% depletion of striatal dopamine levels. The histological signature is the intracellular presence of Lewy bodies—abnormal cytoplasmic inclusions composed primarily of aggregated, misfolded alpha-synuclein protein.

                    THE CARDINAL MOTOR MANIFESTATIONS (TRAP MNEMONIC)

   Cardinal Sign       Clinical Examination Features & Pathophysiology              Distinguishing Diagnostic Clues
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Tremor (Resting)    • 4 to 6 Hz low-frequency "pill-rolling" tremor.             • Characteristically ASYMMETRIC onset (one hand).
                       • Present at complete rest, with the limb fully supported.   • SUPPRESSED during purposeful movement.
                       • Re-emerges after a brief latency when holding a posture.   • Does not involve the head (jaw/chin can shake).
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Rigidity            • Increased resistance to passive joint mobilization.        • Resistance is velocity-INDEPENDENT (unlike spasticity).
                       • "Lead-pipe": uniform, smooth resistance throughout range.  • Froment sign: rigidity accentuates when patient
                       • "Cogwheel": ratcheting resistance caused by superimposed     performs voluntary movement with contralateral limb.
                         resting tremor oscillations on hypertonia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Akinesia /          • OBLIGATORY CRITERION: slowness of movement initiation       • Progressive reduction in SPEED and AMPLITUDE
   Bradykinesia          with progressive fatigue and decrement during rapid          during repetitive movements (finger tapping, toe taps).
                         repetitive movements.                                      • Masked facies (hypomimia), reduced blink rate,
                                                                                      soft monotonous speech (hypophonia), micrographia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Postural            • Loss of normal postural corrective reflexes; retropulsion  • LATE DISEASE FEATURE in idiopathic PD.
   Instability           elicited on the backward pull test.                        • If prominent within first 1-2 years, strongly
                       • Frequent unprovoked falls; inability to recover balance.     suspect Progressive Supranuclear Palsy (PSP).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Additional Motor Signs

• Shuffling, Festinating Gait: The patient ambulates with narrow-based, short, flat-footed shuffling steps. The center of gravity leans forward (propulsion/stooped posture), causing the steps to become progressively faster as if chasing the center of gravity (festination), culminating in freezing of gait.
• En Bloc Turning: Turning requires multiple small, tentative steps (5 to 20 steps to turn 180 degrees) rather than a smooth, single-pivot motion.
• Asymmetric Decreased Arm Swing: One of the earliest physical signs; the affected arm remains immobile or tucked against the flank during ambulation.
• Micrographia: Handwriting starts at normal size but becomes progressively cramped, minuscule, and illegible across the page.

---

Non-Motor Features & Prodromal Parkinsonian Neurodegeneration

Under the Braak staging hypothesis, alpha-synuclein pathology does not originate in the substantia nigra. Instead, Lewy pathology begins years to decades earlier in the peripheral autonomic nervous system (enteric plexus) and the lower brainstem (dorsal motor nucleus of the vagus nerve) and olfactory bulb (Braak stages 1-2), before ascending through the midbrain (stages 3-4) and finally infiltrating the neocortex (stages 5-6). Consequently, non-motor symptoms precede the onset of motor parkinsonism by 5 to 20 years:

1. Hyposmia / Anosmia: Present in >90% of idiopathic PD patients; profound loss of olfactory discrimination occurs years before tremor or bradykinesia.
2. REM Sleep Behavior Disorder (RBD): Degeneration of pontine inhibitory sublaterodorsal nuclei causes loss of normal physiological muscle atonia during REM sleep. Patients physically act out vivid, frightening dreams (punching, thrashing, vocalizing). Over 80% of individuals with idiopathic RBD convert to an overt alpha-synucleinopathy (PD, DLB, or MSA) within 10 to 15 years.
3. Chronic Constipation: Enteric nervous system Lewy body deposition results in profound colonic hypomotility, often present for decades before motor symptoms.
4. Neuropsychiatric Disturbances: Major depressive disorder and generalized anxiety occur in approximately 40% of patients due to early loss of ascending serotonergic (raphe nuclei) and noradrenergic (locus coeruleus) projections.
5. Autonomic Failure: Orthostatic hypotension (drop in SBP >=20 mmHg or DBP >=10 mmHg within 3 minutes of standing), neurogenic bladder (urinary urgency and frequency), and erectile dysfunction.
6. Sialorrhea: Excessive drooling resulting from impaired automatic swallowing mechanics rather than salivary hypersecretion.

---

Clinical Diagnosis & Differential Diagnosis of Atypical Parkinsonian Syndromes

The diagnosis of Parkinson's disease remains fundamentally clinical. Under the Movement Disorder Society (MDS) clinical diagnostic criteria, diagnosis requires:

• Core Criterion: Bradykinesia plus at least one of resting tremor or rigidity.
• Supportive Criteria: Clear, dramatic, and sustained beneficial response to dopaminergic therapy; presence of levodopa-induced peak-dose dyskinesia; asymmetric onset; resting tremor of a limb; and documented olfactory loss.
• Absence of Absolute Exclusion Criteria: Absence of cerebellar signs, supranuclear downward gaze palsy, diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia within the first 5 years, or exposure to dopamine receptor-blocking medications.

                  PARKINSONISM: ATYPICAL & SECONDARY SYNDROMES

   Syndrome                 Distinctive Clinical Hallmarks                                Diagnostic Clues & Neuroimaging
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Progressive Supranuclear • Early falls within first 12 months (axial instability).     • Brain MRI shows midbrain tegmentum atrophy
   Palsy (PSP)              • Vertical SUPRANUCLEAR GAZE PALSY (impaired downward saccades). with preserved pons ("Hummingbird sign").
                            • Severe axial rigidity > appendicular; "surprised" stare.     • Poor/transient response to levodopa.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Multiple System          • Early, profound AUTONOMIC FAILURE (severe orthostatic        • Brain MRI shows pontine T2 cross-hyperintensity
   Atrophy (MSA)              hypotension, urinary incontinence or retention, ED).           ("Hot cross bun sign") and putaminal rim slit.
                            • Striatonigral type (MSA-P): atypical parkinsonism.           • Laryngeal stridor, cold violaceous hands.
                            • Cerebellar type (MSA-C): prominent cerebellar ataxia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Corticobasal             • Asymmetric cortical signs: alien limb phenomenon, limb       • Asymmetric parietal and frontal cortical atrophy.
   Degeneration (CBD)         apraxia, cortical sensory loss (astereognosis), myoclonus.   • Extremely poor levodopa response.
                            • Marked appendicular rigid dystonia.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Drug-Induced             • Subacute, SYMMETRICAL onset of bradykinesia and rigidity.    • Normal DaTscan (SPECT I-123 ioflupane shows
   Parkinsonism (DIP)       • Caused by D2 receptor antagonists: Antipsychotics (Halo-     intact presynaptic dopamine transporters).
                              peridol, Risperidone), Antiemetics (Metoclopramide,          • Resolves weeks to months after offending
                              Prochlorperazine, Promethazine).                              medication is discontinued.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

---

Pharmacotherapy of Parkinson's Disease: Motor Symptoms & Complications

Pharmacological management aims to restore striatal dopaminergic neurotransmission. No current medication has proven neuroprotective or disease-modifying capabilities; therapy is strictly symptomatic.

                  EVIDENCE-BASED PHARMACOTHERAPY FOR PARKINSON'S DISEASE

   Class & Agent            Mechanism of Action          Initial / Target Dose              Adverse Effects & High-Yield Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Dopamine Precursor       Exogenous dopamine precursor IR: 25/100 mg PO TID;              • GOLD STANDARD for motor symptoms.
   • Carbidopa / Levodopa   (levodopa) coupled with      titrate to 50/200 mg TID           • Carbidopa blocks peripheral conversion;
     (Sinemet)              peripheral dopa-decarboxy-   or higher as needed.                 requires >= 75-100 mg carbidopa daily
                            lase inhibitor (carbidopa).                                       to prevent nausea/orthostasis.
                                                                                            • Dietary protein competes for gut absorption.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Non-Ergot Dopamine       Direct stimulation of        Pramipexole: 0.125 mg TID up to    • Preferred in younger patients (<60y) to
   Agonists                 postsynaptic striatal D2     1.5 mg TID; Ropinirole: 0.25 mg     delay motor fluctuations.
   • Pramipexole            and D3 receptors.            TID to 8 mg TID; Rotigotine:       • ADVERSE: IMPULSE CONTROL DISORDERS (15-20%),
   • Ropinirole                                          2 mg/24h patch up to 8 mg/24h.       sudden daytime sleep attacks, orthostasis.
   • Rotigotine (Patch)
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   MAO-B Inhibitors         Irreversibly inhibits        Rasagiline: 0.5 to 1 mg daily;     • Modest symptomatic motor benefit;
   • Rasagiline             monoamine oxidase-B,         Selegiline: 5 mg BID (with           often used as initial monotherapy in mild disease.
   • Selegiline             blocking central dopamine    breakfast and lunch).              • Insomnia (selegiline metabolizes to amphetamine);
                            metabolism.                                                       caution with potent serotonergic agents.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   COMT Inhibitors          Inhibits catechol-O-methyl-  Entacapone: 200 mg co-administered • ONLY effective when co-administered with levodopa.
   • Entacapone             transferase, blocking        with each levodopa dose            • Prolongs levodopa half-life; used to manage
                            peripheral conversion of     (up to 8 times daily).               "wearing-off" motor fluctuations.
                            levodopa to 3-OMD.                                              • Harmless orange-brown urine discoloration.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   NMDA Receptor            Uncompetitive NMDA receptor  100 mg PO BID to TID;              • Specifically reduces LEVODOPA-INDUCED
   Antagonist               antagonist; stimulates       extended-release formulations        DYSKINESIAS without worsening parkinsonism.
   • Amantadine             dopamine release/synthesis.  available.                         • Livedo reticularis (lace-like violaceous skin),
                                                                                              ankle edema, confusion, hallucinations.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Anticholinergics         Blocks striatal muscarinic   0.5 to 2 mg PO TID                 • Useful for prominent resting tremor in
   • Trihexyphenidyl        acetylcholine receptors.     (titrate very slowly).               younger patients (<60 years).
   • Benztropine                                                                            • AVOID IN ELDERLY: triggers severe delirium,
                                                                                              urinary retention, dry mouth, blurred vision.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Carbidopa / Levodopa (Sinemet)

• Pharmacological Mechanism: Levodopa is the metabolic precursor to dopamine. Unlike dopamine, levodopa crosses the blood-brain barrier via large neutral amino acid transporters (LNAA). Carbidopa is a peripheral dopa-decarboxylase inhibitor that does not cross the blood-brain barrier. By preventing peripheral decarboxylation of levodopa into dopamine in the gut and systemic circulation, carbidopa increases brain levodopa delivery from 1% to over 10% and eliminates peripheral dopamine toxicity (severe nausea, vomiting, orthostatic hypotension, cardiac arrhythmias). A minimum of 75 to 100 mg of carbidopa per day is required to saturate peripheral enzymes.
• Dietary Competition: Levodopa competes with dietary neutral amino acids for absorption across the intestinal mucosa and transport across the blood-brain barrier. Patients with advanced fluctuations should take levodopa 30 to 60 minutes before meals or avoid high-protein meals during the day.
• Long-Term Motor Complications: After 5 to 10 years of levodopa therapy, >50% of patients develop disabling motor complications:
  1. "Wearing-Off" (End-of-Dose Deterioration): The clinical benefit of a levodopa dose shortens from 4-6 hours down to 2-3 hours, with motor parkinsonism re-emerging before the next scheduled dose. Management: Increase dosing frequency (fractionation), switch to extended-release formulations, or add a COMT inhibitor (entacapone) or MAO-B inhibitor (rasagiline) to prolong levodopa half-life.
  2. Levodopa-Induced Dyskinesias (LID): Involuntary choreic, athetoid, or ballismic movements occurring at peak plasma levodopa levels. Management: Reduce individual levodopa doses while increasing frequency, or add Amantadine (the only drug specifically approved for peak-dose dyskinesia).

2. Dopamine Agonists & The Warning on Impulse Control Disorders

• Role: Non-ergot dopamine agonists directly stimulate striatal D2 and D3 receptors. They have longer half-lives than levodopa, providing more continuous dopaminergic stimulation. In patients <60 years of age, initial monotherapy with pramipexole or ropinirole is often considered to postpone the onset of levodopa-induced dyskinesias.
• Impulse Control Disorders (ICDs): Up to 15% to 20% of patients taking dopamine agonists develop severe, destructive impulse control disorders due to excessive stimulation of dopamine D3 receptors localized to the ventral striatum (nucleus accumbens) and mesolimbic reward pathways. Behaviors include pathological gambling, hypersexuality, compulsive shopping/spending, and binge eating. Patients frequently conceal these behaviors out of shame. Clinicians must specifically inquire about financial, sexual, and eating habits at every visit. When identified, the dopamine agonist must be slowly tapered to avoid Dopamine Agonist Withdrawal Syndrome (DAWS) (profound dysphoria, anxiety, suicidal ideation) while substituting levodopa.
• Sudden Daytime Sleep Attacks: Dopamine agonists can induce irresistible, sudden somnolence without warning while operating machinery or driving; patients must be cautioned accordingly.

---

Essential Tremor: Clinical Characteristics, Genetics & Pathophysiology

Essential Tremor (ET) is the most prevalent movement disorder encountered in clinical medicine, affecting approximately 4% to 5% of adults aged >65 years. More than 50% of patients report a positive family history with an autosomal dominant pattern of inheritance with variable penetrance ("familial tremor"). Pathophysiologically, ET is considered an olivocerebellar network disorder, characterized by abnormal rhythmic oscillation in the cerebello-thalamo-cortical circuit.

                  DIFFERENTIAL DIAGNOSIS OF COMMONLY ENCOUNTERED TREMORS

   Feature          Parkinsonian Tremor               Essential Tremor (ET)             Intention / Cerebellar Tremor
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Tremor Frequency 4 to 6 Hz (Slow)                  8 to 12 Hz (Rapid)                3 to 5 Hz (Slow, irregular)
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Primary State    RESTING tremor; limb fully        ACTION tremor; kinetic (during    INTENTION tremor; absent at rest;
                    supported against gravity         purposeful goal-directed tasks)   dramatically worsens as limb
                                                      and POSTURAL (arms outstretched)  approaches the visual target
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Symmetry         ASYMMETRIC onset (one hand/foot)  BILATERAL, SYMMETRICAL onset      Variable; usually unilateral or
                                                      (both hands/arms)                 ipsilateral to cerebellar lesion
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Body Regions     Hands, feet, jaw, lips;           Hands, wrists, HEAD (titubation), Extremities; associated with
   Involved         SPARES THE HEAD AND VOICE         and VOCAL CORDS; SPARES LEGS      dysmetria, dysdiadochokinesia
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Response to      None                              MARKED TEMPORARY REDUCTION        None
   Ethanol                                            in tremor amplitude
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Associated Signs Bradykinesia, rigidity, masked    Isolated tremor; NO rigidity,     Gait ataxia, nystagmus, dysarthria,
                    facies, shuffling festinating     NO bradykinesia, NO masked        past-pointing on finger-to-nose
                    gait, loss of arm swing           facies (pure kinetic syndrome)
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Presentation & The Alcohol Pearl

• The tremor is an 8 to 12 Hz postural and kinetic action tremor. It is absent at complete rest. It manifests when the patient holds the upper extremities outstretched against gravity (postural tremor) or performs goal-directed movements (kinetic tremor)—such as drinking soup from a spoon, bringing a cup of water to the lips, buttoning a shirt, or drawing an Archimedes spiral.
• Head involvement is frequent, presenting as a rhythmic vertical ("yes-yes") or horizontal ("no-no") titubation.
• Vocal involvement manifests as a tremulous, wavering, quavering voice.
• The Alcohol Phenomenon: Up to 60% to 70% of patients experience a dramatic, transient (1-2 hour) reduction in tremor amplitude after consuming a small amount of ethanol (e.g., one glass of wine or beer). Ethanol enhances central GABAergic inhibition within the olivocerebellar circuit. While pathognomonic, self-medication with alcohol carries a risk of secondary alcohol use disorder.

---

Evidence-Based Pharmacotherapy & Interventional Therapies for Essential Tremor

Pharmacotherapy is indicated when the tremor produces functional impairment in occupational tasks, self-care, or social interactions.

1. First-Line Pharmacotherapies

• Propranolol: A non-selective beta-adrenergic blocker. Dosage starts at 40 mg daily (immediate-release divided BID or long-acting ER 60-80 mg daily), titrated up to 120 to 320 mg daily. It suppresses peripheral beta-2 receptors in muscle spindles.
  • Contraindications: Symptomatic bradycardia, second- or third-degree AV block, decompensated heart failure, and active asthma or severe bronchospastic COPD.
• Primidone: An antiepileptic barbiturate prodrug metabolized to phenobarbital and phenylethylmalonamide (PEMA). Dosage starts extremely low at 12.5 to 25 mg PO at bedtime (to prevent acute toxic first-dose vertigo, nausea, sedation, and ataxia), then slowly escalated weekly up to a target maintenance of 50 to 250 mg PO three times daily (max 750 mg/day). Equiefficacious to propranolol.
• Combination Therapy: In patients with severe or refractory tremor, propranolol and primidone can be combined synergistically.

2. Second-Line Therapies

• Topiramate (100 to 400 mg daily), Gabapentin (300 to 1800 mg daily in divided doses), or Alprazolam (low-dose benzodiazepine, reserved for high-anxiety performance situations due to dependence risk).

3. Advanced Interventional & Surgical Therapies

• Deep Brain Stimulation (DBS): High-frequency electrical stimulation of the ventral intermediate (VIM) nucleus of the thalamus provides up to 80% tremor suppression in severe, medication-refractory, disabling essential tremor.
• MRI-Guided Focused Ultrasound (MRgFUS): Non-invasive, incisionless thermal ablation targeting the unilateral VIM thalamic nucleus using high-intensity focused ultrasound beams through the intact cranium under real-time thermal MRI guidance.